China : Merck Accelerates Mobius Single-Use Manufacturing in Wuxi.
Merck, a leading science and technology company, today announced an additional investment to accelerate Mobius single-use manufacturing in Wuxi, China. This investment follows a year after Merck announced its 80m Life Science investment in Nantong, China in November 2016.
As a leading Life Science solutions provider, we are committed to playing an active role in Chinas transformation into an innovation-driven economy, said Andrew Bulpin, head of Process Solutions, Life Science at Merck. This investment allows us to accelerate the development and manufacturing of biosimilars for our customers. It also demonstrates our resolve to fulfil and upgrade the life science value chain in China.
China is fast becoming a biotech powerhouse with a promising biosimilar industry. Single-use capability is critical for biosimilar development and manufacturing because of their flexibility and efficiency.
The investment demonstrates Mercks commitment to support the industrys fast growth by providing a wide range of leading, innovative solutions for customers and partners in China. Located in Wuxi China, the site expansion to add Mobius manufacturing is expected to be completed in the second half of 2018.
Merck recently announced additional investments of about 40m to build a robust supply chain with two new Life Science manufacturing and distribution sites in South Korea and India, and the single-use manufacturing facility in China.
[c] 2018 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 24, 2018|
|Previous Article:||Canada : Loblaw Reports 2017 Fourth Quarter and Fiscal Year Ended December 30, 2017 Results.|
|Next Article:||Korea Republic of : Merck Signs Agreement with Incheon Free Economic Zone to Build Cell Culture Facility in South Korea.|